

Sanofi  
Form 6-K  
March 07, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2016**

**Commission File Number: 001-31368**

**SANOFI**

**(Translation of registrant's name into English)**

**54, rue La Boétie, 75008 Paris, FRANCE**

Edgar Filing: Sanofi - Form 6-K  
**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If  Yes  marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  
82-

In March 2016, Sanofi issued the statements attached hereto as Exhibits 99.1 to 99.3 which are incorporated herein by reference.

**Exhibit List**

Exhibit No.	Description
Exhibit 99.1	Press release dated March 4, 2016: Filing of the 2015 U.S. Form 20-F and French Document de Référence containing the Annual Financial Report
Exhibit 99.2	Press release dated March 3, 2016: Sanofi Genzyme Presents Results from Phase 1/2 Study of Investigational Second-Generation Therapy for Pompe Disease
Exhibit 99.3	Press release dated March 3, 2016: Sanofi's Board of Directors Proposes Appointment of Diane Souza and Thomas Südhof, MD as New Independent Directors

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 7, 2016

SANOFI

By /S/ Alexandra Roger

Name: Alexandra Roger

Title: Head of Securities Law and Capital Markets

**Exhibit Index**

Exhibit No.	Description
Exhibit 99.1	Press release dated March 4, 2016: Filing of the 2015 U.S. Form 20-F and French Document de Référence containing the Annual Financial Report
Exhibit 99.2	Press release dated March 3, 2016: Sanofi Genzyme Presents Results from Phase 1/2 Study of Investigational Second-Generation Therapy for Pompe Disease
Exhibit 99.3	Press release dated March 3, 2016: Sanofi's Board of Directors Proposes Appointment of Diane Souza and Thomas Südhof, MD as New Independent Directors